Lau A - Search Results

1

Correction to: Comparison of the clinical effectiveness and safety between the use of denosumab vs bisphosphonates in renal transplant patients.

McKee H, Ioannidis G, Lau A, Treleaven D, Gangji A, Ribic C, Wong-Pack M, Papaioannou A, Adachi JD. McKee H, et al. Among authors: lau a. Osteoporos Int. 2020 May;31(5):981. doi: 10.1007/s00198-020-05381-5. Osteoporos Int. 2020. PMID: 32189031

2

Improvement in health-related quality of life in osteoporosis patients treated with teriparatide.

Lau AN, Ali SH, Sawka AM, Thabane L, Papaioannou A, Gafni A, Adachi JD. Lau AN, et al. BMC Musculoskelet Disord. 2008 Nov 7;9:151. doi: 10.1186/1471-2474-9-151. BMC Musculoskelet Disord. 2008. PMID: 18990249 Free PMC article.

3

Resolution of osteonecrosis of the jaw after teriparatide [recombinant human PTH-(1-34)] therapy.

Lau AN, Adachi JD. Lau AN, et al. J Rheumatol. 2009 Aug;36(8):1835-7. doi: 10.3899/jrheum.081176. J Rheumatol. 2009. PMID: 19671824 No abstract available.

4

What are the beliefs, attitudes and practices of front-line staff in long-term care (LTC) facilities related to osteoporosis awareness, management and fracture prevention?

Lau AN, Ioannidis G, Potts Y, Giangregorio LM, Van der Horst ML, Adachi JD, Papaioannou A. Lau AN, et al. BMC Geriatr. 2010 Oct 8;10:73. doi: 10.1186/1471-2318-10-73. BMC Geriatr. 2010. PMID: 20929589 Free PMC article.

5

Role of teriparatide in treatment of glucocorticoid-induced osteoporosis.

Lau AN, Adachi JD. Lau AN, et al. Ther Clin Risk Manag. 2010 Oct 21;6:497-503. doi: 10.2147/TCRM.S7776. Ther Clin Risk Manag. 2010. PMID: 21063460 Free PMC article.

6

The current practice of screening, prevention, and treatment of androgen-deprivation-therapy induced osteoporosis in patients with prostate cancer.

Al-Shamsi HO, Lau AN, Malik K, Alamri A, Ioannidis G, Corbett T, Adachi JD, Papaioannou A. Al-Shamsi HO, et al. Among authors: lau an. J Oncol. 2012;2012:958596. doi: 10.1155/2012/958596. Epub 2012 Apr 30. J Oncol. 2012. PMID: 22619678 Free PMC article.

7

Systemic lupus erythematosus, osteoporosis, and fractures.

Adachi JD, Lau A. Adachi JD, et al. Among authors: lau a. J Rheumatol. 2014 Oct;41(10):1913-5. doi: 10.3899/jrheum.140919. J Rheumatol. 2014. PMID: 25275093 No abstract available.

8

The relationship between long-term proton pump inhibitor therapy and skeletal frailty.

Lau AN, Tomizza M, Wong-Pack M, Papaioannou A, Adachi JD. Lau AN, et al. Endocrine. 2015 Aug;49(3):606-10. doi: 10.1007/s12020-015-0576-z. Epub 2015 May 7. Endocrine. 2015. PMID: 25948072 Free PMC article. Review.

9

The Effects of Noncompliance to Prolia (Denosumab) on the Changes in Bone Mineral Density: A Retrospective Review.

Wong-Pack M, Kalani A, Hordyk J, Ioannidis G, Bensen R, Bensen WG, Papaioannou A, Adachi JD, Lau AN. Wong-Pack M, et al. Among authors: lau an. J Osteoporos. 2016;2016:7903128. doi: 10.1155/2016/7903128. Epub 2016 Jan 4. J Osteoporos. 2016. PMID: 26881176 Free PMC article.

10

A Comparison of CAROC and FRAX in Patients with Fragility Fracture.

Adachi JD, Lau A, Papaioannou A. Adachi JD, et al. Among authors: lau a. J Rheumatol. 2016 Aug;43(8):1456-7. doi: 10.3899/jrheum.160712. J Rheumatol. 2016. PMID: 27481988 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,267 results

Search Page

Filters